Cybin Secures $175 Million in Registered Direct Offering to Advance Mental Health Treatments
Cybin Inc. has raised $175 million through a registered direct offering, providing crucial funding to advance its late-stage clinical trials for novel mental health treatments including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.
Cybin Inc. has announced a significant $175 million registered direct offering, positioning the neuropsychiatry company to advance its pipeline of next-generation mental health treatments. The offering includes 22,277,750 common shares and pre-funded common share purchase warrants priced at $6.51 per share, generating aggregate gross proceeds of $175,009,911.45. Each share or pre-funded warrant comes with 0.35 of one common share purchase warrant exercisable at $8.14 per share.
The financing attracted participation from both new and established healthcare investors, including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and Acorn Bioventures. Other significant participants include Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group. This broad investor support underscores confidence in Cybin's clinical development programs.
The timing of this substantial capital raise coincides with critical milestones in Cybin's clinical development. The warrant exercise period extends until the earlier of June 30, 2027, 30 days after topline data release for the APPROACH trial of CYB003 in major depressive disorder, or 30 days following an acceleration notice if the NYSE American closing price equals or exceeds $19.53 for five consecutive trading days. This structure aligns investor interests with key clinical and market milestones.
Cybin is advancing CYB003, a proprietary deuterated psilocin analog that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is currently in Phase 3 studies for adjunctive treatment of major depressive disorder. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder. Additional details about Cybin's development programs are available at https://ibn.fm/CYBN.
This funding comes at a pivotal moment for mental healthcare innovation, as traditional treatments often provide inadequate relief for many patients. Cybin's approach focuses on developing novel compounds that target 5-HT receptors, potentially offering more effective and durable results for individuals suffering from mental health conditions. The full press release detailing the offering terms can be accessed at https://ibn.fm/TPxvo.
The $175 million capital infusion represents one of the larger financings in the neuropsychiatry sector this year and signals growing investor confidence in psychedelic-inspired medicines as viable treatment options. With mental health disorders affecting millions worldwide and current treatments often falling short, Cybin's clinical programs address a substantial unmet medical need. The company's operational presence across Canada, the United States, the United Kingdom and Ireland positions it to advance these treatments through global regulatory pathways.